VCIM
HRTX icon

Velan Capital Investment Management’s Heron Therapeutics HRTX Stock Holding History

Velan Capital Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7M Hold
8,753,290
– – 4.39% 8
2025
Q4 		$11.4M Hold
8,753,290
– – 6.6% 4
2025
Q3 		$11M Buy
8,753,290
+1,766,546
+25% +$2.8M 10.36% 1
2025
Q2 		$14.5M Hold
6,986,744
– – 14.29% 1
2025
Q1 		$15.4M Hold
6,986,744
– – 15.81% 1
2024
Q4 		$10.7M Hold
6,986,744
– – 9.22% 3
2024
Q3 		$13.9M Hold
6,986,744
– – 13% 4
2024
Q2 		$24.5M Hold
6,986,744
– – 14.01% 3
2024
Q1 		$19.4M Hold
6,986,744
– – 8.79% 5
2023
Q4 		$11.9M Hold
6,986,744
– – 6.93% 3
2023
Q3 		$7.2M Buy
6,986,744
+2,486,744
+55% +$3.54M 5.8% 4
2023
Q2 		$5.22M Hold
4,500,000
– – 4.85% 6
2023
Q1 		$6.79M Buy
4,500,000
+2,000,000
+80% +$5.01M 5.79% 6
2022
Q4 		$6.25M Buy
+2,500,000
New +$8.05M 5.52% 8

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
CPC
Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return

Velan Capital Investment Management's HRTX Position: Q1 2026 in Review

Velan Capital Investment Management held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 8,753,290 shares worth $7M. The position accounts for 4.39% of the portfolio, ranked #8.

Velan Capital Investment Management first reported a position in HRTX in Q4 2022 and has held it in 14 quarters since. The position peaked at $24.5M in Q2 2024. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Velan Capital Investment Management held 8,753,290 shares of Heron Therapeutics worth $7M as of Q1 2026.
  • Velan Capital Investment Management left its Heron Therapeutics share count unchanged in Q1 2026.
  • Heron Therapeutics made up 4.39% of Velan Capital Investment Management's portfolio in Q1 2026, its #8 holding.
  • Velan Capital Investment Management first reported a position in Heron Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Velan Capital Investment Management's Heron Therapeutics position peaked at $24.5M in Q2 2024.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.